Mass General Researchers Link Poor Lung Cancer Survival to Mutations in Two Genes | GenomeWeb

Patients with lung cancer who have a certain gene mutation are more likely to respond to the chemotherapeutic agents cisplatin or carboplatin, according to research conducted at the Massachusetts General Hospital.

Results of this retrospective study may help oncologists better select patients for these commonly prescribed drugs. “We hope that this type of research will one day enable doctors and patients to make more informed decisions about chemotherapy treatments,” study author Sarada Gurubhagavatula said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.